In the first half of 2023, antitrust enforcers remained remarkably busy both in the United States (US) and across the European Union (EU). The US Department of Justice’s (DOJ’s) Antitrust Division (Division) and the Federal...more
The US Court of Appeals for the Seventh Circuit affirmed that welfare benefit plans that bought the drug Humira did not have valid antitrust claims against the patent owner. The Court found that amassing patents by itself is...more
8/11/2022
/ Antitrust Provisions ,
Antitrust Violations ,
Biologics Price Competition and Innovation Act of 2009 ,
Biosimilars ,
Dismissals ,
Health and Welfare Plans ,
Patent Litigation ,
Patent Ownership ,
Patents ,
Pharmaceutical Patents ,
Sherman Act ,
Walker Process Claims